Get the Stockscreener App
6.29
9.97%
0.57
After Hours:
6.34
0.05
+0.79%
Evaxion A S Adr stock is traded at $6.29, with a volume of 1.44M.
It is up +9.97% in the last 24 hours and up +113.22% over the past month.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
See More
Previous Close:
$5.72
Open:
$5.96
24h Volume:
1.44M
Relative Volume:
1.03
Market Cap:
$39.73M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.4493
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
+41.67%
1M Performance:
+113.22%
6M Performance:
+355.80%
1Y Performance:
-55.70%
1-Day Range:
$5.85
$7.35
1-Week Range:
$4.38
$7.35
52-Week Range:
$1.20
$15.50
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
6.29 | 36.13M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting - GlobeNewswire Inc.
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright - TipRanks
Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck - TipRanks
Evaxion A/S (NASDAQ:EVAX) Trading Down 0.7% – Should You Sell? - Defense World
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion secures Nasdaq listing with equity boost - Investing.com
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data - Yahoo Finance
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):